MIRAMAR, Fla., Aug. 20, 2021 (GLOBE NEWSWIRE) — Stemtech Corporation (“Stemtech”), a leading nutraceutical company and a pioneer in the field of stem cell nutrition, announced today that it has executed a definitive agreement with Globe Net Wireless Corp. (GNTWD) to merge into the public company.
Stemtech Corporation was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, which was founded in 2005. From 2010 through 2015, Stemtech International, Inc. was recognized four separate times by the Inc. 5000 Fastest-Growing Companies list. In 2018, the Company underwent an extensive executive reorganization, positioning the Company to begin expansion once again as a leading force in cellular nutrition. Known as the Stem Cell Nutrition Company®, the Company has a history of innovation, and was the first to market in the category of stem cell nutrition. According to market research firm Fortune Business Insights, the global nutraceuticals market is predicted to grow from $352.92 billion in 2021 to $658.11 billion in 2028 at a Compound Annual Growth Rate (CAGR) of 9.3% in the forecast period 2021-2028.
“Completing our public listing is a significant milestone in the history of Stemtech,” said Chairman and CEO Charles Arnold. “Becoming a publicly traded company gives us the platform to continue our leadership role in the growing nutraceutical sector, as well as providing better access to quality capital, enabling us to expand operations and significantly bolster our marketing efforts, both domestically and internationally. Stemtech has a unique corporate culture that has been forged over 16 years of its history, with an extremely loyal base of customers and independent distributors that believe in our mission of fostering innovation, wellness and prosperity for all of our key stakeholders.”
“The Company’s vision is to ramp-up production and delivery of our innovative stem cell nutrition products to a global audience,” Mr. Arnold continued. “With increasing interest in developments in the stem cell industry, we believe that Stemtech is strongly positioned to capitalize on the growth in this sector. Additionally, as the company that invented the stem cell nutrition category, we plan to further fund research and development efforts and to bring new groundbreaking products to market.” According to Research and Markets, a market research firm, the Global Stem Cell Therapy Market size is projected to grow at a Compound Annual Growth Rate (CAGR) of 19.07% from 2020 to 2026.
Stemtech specializes in creating products and formulas that are patent-protected in the U.S. and international markets. The Company’s patented formulas help the release, circulation and migration of the body’s adult stem cells from its bone marrow. Its products are all-natural and plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplemental Health and Education Act (DSHEA). The Company’s primary marketing and distribution channel is through a direct sales structure, which offers supplemental and residual income earning potential to Independent Business Partners (IBPs). The direct sales industry currently represents $192 billion dollars in annual sales, according to the Direct Selling Association (DSA). The Company has also expanded into sub-licensing agreements in select international markets.
Additional information regarding the transaction is set forth in the Globe Net Wireless Corp. (GNTWD) Form 8K dated August 20, 2021, which was filed with the Securities and Exchange Commission.
About Stemtech Corporation
Stemtech Corporation, a leading nutraceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations from its predecessor Stemtech International, which was founded in 2005. From 2010 through 2015, Stemtech International, Inc., was recognized four separate times on the Inc. 5000 Fastest-Growing Companies list. In 2018, the Company underwent an extensive executive reorganization, and continued operations under new leadership. Stemtech specializes in creating products and formulas that are patent-protected in the U.S. and in select international markets. The Company’s patented formulas help the release, circulation and migration of the body’s adult stem cells from its bone marrow. The Company markets its products under the following brands: RCM System, stemrelease3™, Stemflo® MigraStem™, DermaStem®, DermaStem Lift, OraStem® (Oral Health Care), and D-Fuze™. Its products are all-natural and plant-based and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplemental Health and Education Act (DSHEA). For more information, please visit www.stemtech.com.
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on July 13th, 2021. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation which are condoned by the Company must emanate from the Company itself and bear our name as its Source.
For Further Information, Contact:
Investors: Frank J. Pena, 908-675-0581, [email protected]